consequences of CHD7 mutations. Thus, the diagnosis of the syndrome is still largely based on medical features, even though no single feature is universally present or sufficient for clinical diagnosis [Zentner et al., 2010] .
Case Report
We report the case of a 27-year-old male patient with the diagnosis of typical CHARGE syndrome ( table 1 ) [Verloes, 2005] . The patient underwent surgery during childhood for a bilateral cleft lip repair and presented with complete cleft palate, bilateral coronal synostosis, congenital dislocation of both hips, and persistent ductus arteriosus with a discrete subaortic fibrous ring. The patient was also receiving testosterone treatment secondary to a hypogonadotropic hypogonadism with associated bilateral cryptorchidism and testicular atrophy. No previous genetic syndromes were reported in his family background, and the patient had a normal 46,XY karyotype. Although intellectual disability was seen, the patient presented with slight growth retardation (168 cm height and 57 kg weight).
On physical examination, the patient presented with plagiocephaly with scars secondary to previous craniotomies, broad forehead, short neck, broad nasal base with repaired cleft lip and palate, normal eyebrows, eyelashes and hair, hypertelorism with exophthalmos, and bilateral ear abnormalities ( fig. 1 A, B) . Also, after a left ocular trauma, the patient showed a retinal detachment with an associated band keratopathy and high myopia chorioretinitis in the right eye. Dentition was normal with no dental caries. No digital abnormalities were observed.
A cerebral magnetic resonance imaging revealed moderate dilatation of the ventricular system without hydrocephalus, mild cerebral atrophy ( fig. 1 C) , intervertebral osteochondrosis of C4-C5, C5-C6 and C6-C7, C4-C5 discrete right neural foramen stenosis without radicular compression ( fig. 1 D) , left orbital cavity hypoplasia with proptosis of the right eyeball, and hypoplasia of the turbinates.
Fibrobronchoscopy showed right septoturbinal synechiae secondary to a previous rhinoplasty with normal nasopharynx and nostrils. The patient also suffered from a total loss of smell since he was a child with no previous data of inflammation or injury.
Temporal bone computerized tomography showed bilateral mastoid air cell sclerosis, normal pneumatized tympanic cavities, hammer head sclerosis with partial anvil and total stirrup aplasia ( fig. 2 A) , complete absence of the semicircular canals ( fig. 2 B) , bilateral hypoplasia of the cochleas ( fig. 2 C) , and dysplasia of both vestibules ( fig. 2 D) . These findings are more pronounced in the left ear. Liminal pure tone audiometry performed in a free sound field, without hearing aids, indicated a profound hearing loss in both ears: the right ear revealed an air conduction between 101-110 dB and a bone conduction between 40-80 dB, and the left ear had an air conduction loss of 120 dB and no bone conduction at all. A twosyllable word test in a free-field (65 dB), with the hearing aid in the 
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Rhombecephalic dysfunction (brainstem dysfunctions, cranial nerve VII to XII palsies and neurosensory deafness) Hypothalamo-hypophyseal dysfunction (including growth hormone and gonadotropin defects) Malformation of the ear (middle or external) Malformation of mediastinal organs (heart, esophagus) Intellectual disability Typical CHARGE: 3 majors or 2 majors + 2 minors Partial CHARGE: 2 majors + 1 minor Atypical CHARGE: 2 majors but no minors or 1 major + 3 minors right ear, showed a 0% discrimination, increasing to 50% with lip reading. No previous history of otitis was referred.
Abdominal ultrasound showed normal gallbladder, spleen, pancreas, and kidneys. The electrocardiogram showed sinus rhythm with left ventricular hypertrophy, and the transthoracic echocardiogram evidenced a subaortic discrete fibrous ring ( fig. 3 ) with moderate subaortic gradient (echocardiographic peak gradient of 64 mm Hg and mean gradient of 37 mm Hg), mild-moderate aortic regurgitation, a bicuspid aortic valve, and left ventricular hypertrophy.
The patient was under testosterone treatment since he was 13 years old due to a hypogonadotropic hypogonadism with associated bilateral cryptorchidism and testicular atrophy. Serum follicle stimulating hormone levels were 0.06 mU/ml (normal range: 1.5-14 mU/ml), and luteinizing hormone was below 0.07 mU/ml (normal range: 1.4-7.7 mU/ml). Luteinizing hormone-releasing hormone stimulation test showed 0.04 ng/ml of free testosterone (normal range: 0-0.9 ng/ml). Replacement therapy with a combination of testosterone propionate and testosterone enanthate (250 mg every 21 days) resulted in a concentration of testosterone of 1.82 ng/ ml. Serum glucose, creatinine, cholesterol, thyroid-stimulating hormone, and cortisol levels were normal.
Exons and flanking regions of the CHD7 gene were subjected to mutation detection analysis. Heterozygote sequencing of the patient's genomic DNA isolated from peripheral blood cells revealed a cytosine duplication (GRCh37.p10; chr8; rs61654318) within the coding sequence of exon 2 at nucleotide 327 from the translation start site (c.327dupC). This results in a valine to arginine change at protein position 110 and a shift in the reading frame that caused a premature stop 21 amino acids downstream of this position (NP_060250.2; p.Val110Argfs * 22). The resulting polypeptide would be devoid of any predicted functional domain of the CHD7 protein. This mutation was absent in genomic DNA isolated from peripheral blood cells from both parents and an unaffected sibling.
Discussion
CHARGE syndrome results from a dysblastogenetic and dysneurulative process mostly caused by heterozygous mutations in the CHD7 gene, shown to be essential for the formation of multipotent migratory neural crest cells [Bajpai et al., 2010] . Indeed, the CHARGE phenotype is supposed to result from abnormal differentiation of cephalic mesoderm and ectoderm, abnormal setting and interaction of neural crests with the cephalic mesoderm and the developing forebrain, and altered development of the rhombencephalon out of which the neural crest cells have migrated during the 3rd and 9th week of gestation [Lin et al., 1990] .
Regardless of the 3 major criteria suggested by Verloes [2005] , which refer to 3 nonoverlapping embryological territories (otic placode, optic vesicle and midcranial medial structures), characteristic CHARGE syndrome ear may be seen in 80-100% of the patients. While semicircular canal anomalies show a high specificity for this syndrome, cochlear defects do not, as the latter can also be seen in nonsyndromic deafness and in many other unrelated disorders. Concerning eye malformations, unilateral or bilateral coloboma of the iris, retina, choroid, or disc, with or without microphthalmos, are found in 80-90% of CHARGE patients. Retinal colobomas are much more prevalent than iris colobomas and are associated with microphthalmia in those more severe cases. Nonetheless, ocular colobomas can also be seen in isolation and in an impressive number of multisystem syndromes. Finally, unilateral or bilateral choanal atresias or stenoses can be seen in 50-60% of the patients with CHARGE syndrome. However, when orofacial clefting is present, the choanae are usually patent, so cleft lip and/or palate may be a substitute for a choanal atresia [Blake et al., 1998 ]. Nonetheless, stenoses of choanae may be also encountered as an isolated birth defect or as a part of other uncorrelated disorders such as chromosome abnormalities, craniosynostosis disorders or Treacher Collins syndrome [Lalani et al., 1993] . On the other hand, the 5 minor criteria suggested by Verloes [2005] ( table 1 ) were selected as an attempt to define CHARGE by primary, not overlapping disturbances, rather than by secondary features. CHD7 belongs to a large family of evolutionarily conserved proteins thought to play a general role in chromatin organization, therefore affecting a large number of developmental pathways, which would explain the pleiotropic nature of the phenotypic spectrum of CHARGE mutations [Sanlaville and Verloes, 2007] . Over 500 mutations have been found throughout the CHD7 gene . Of these, which are predominantly heterozygous point mutations, approximately 46% are nonsense, 24% cause frameshifts, 15% are missense, 10% affect splice sites, and 3% are intronic mutations. Only 1% are chromosomal rearrangements, and another 1% are caused by whole-gene or larger chromosomal deletions [Jongmans et al., 2006; Zentner et al., 2010; Janssen et al., 2012] . Both haploinsufficiency, caused by loss-of-function alleles, and dominant negative forms of the protein are believed to be responsible for the CHARGE phenotype [Bajpai et al., 2010; Bergman et al., 2011] . In the case we describe, we have found a novel insertion in exon 2 of the CHD7 gene, leading to a frameshift that results in a short polypeptide devoid of any known functional domain, and therefore, it is unlikely to be a dominant negative form of the protein. Therefore, we hypothesize that this mutation represents a null allele, causing disease due to haploinsufficiency. This is in agreement with previous findings suggesting that a full genetic dosage is required for complete function of CHD7 . This novel mutation was sporadic, as in most CHARGE cases described to date, therefore discarding family inheritance with asymptomatic parents [Pauli et al., 2009] . Heterozygous sequencing of DNA isolated from peripheral blood from both parents discarded somatic mosaicism, although germline mosaicism can not be discarded and could be the origin of the mutation as it has been described in similar cases . In this context, when a parent of the proband has CHARGE syndrome or has a CHD7 mutation, the risk to the sibs of inheriting the mutation is 50%. Meanwhile, if neither parent is affected, the empiric risk is approximately 1-2%, most likely attributable to germline mosaicism [Lalani et al., 1993] .
The patient presented with a clear CHARGE phenotype, similarly to other patients described with other frameshift mutations in exon 2 [Lalani et al., 2006] , enlarging the spectrum of mutations leading to CHARGE syndrome. Heterozygous mutations in the CHD7 gene may be found, depending on the patient cohort analyzed, in over 95% of the patients [Jongmans et. al, 2008] who fulfill the criteria of Blake et al. [1998] or Verloes [2005] ( table 1 ). CHD7 mutation-positive individuals present more frequently with inner ear malformations, facial nerve palsy and ocular colobomas, while mutation-negative patients are less likely to present with delayed growth and development alterations. However, no significant differences have been seen between mutation-positive and mutation-negative patients in relation to heart defects, choanal atresia and endocrine, urogenital, spinal, and skeletal abnormalities [Zentner et al., 2010] .
Due to the clinical variability of the CHARGE syndrome and because most of the patients with a CHD7 mutation fulfill the criteria of Blake et al. [1998] or Verloes [2005] ( table 1 ), mutation screening of the CHD7 gene should be emphasized as a useful tool in patients with clinical suspicion. This is especially important in patients with mild CHARGE phenotype, asymptomatic or mosaic parents which may lead to parental transmission or patients diagnosed with Kallmann syndrome or hypogonadotropic hypogonadism presenting with minimal additional features of CHARGE syndrome [Blake et al., 2011] .
